2395 logo

Shin Nippon Biomedical Laboratories Stock Price

Symbol: TSE:2395Market Cap: JP¥58.2bCategory: Pharmaceuticals & Biotech

2395 Share Price Performance

Community Fair Values

    Recent 2395 News & Updates

    No updates

    Shin Nippon Biomedical Laboratories, Ltd. Key Details

    JP¥32.4b

    Revenue

    JP¥15.5b

    Cost of Revenue

    JP¥17.0b

    Gross Profit

    JP¥12.0b

    Other Expenses

    JP¥4.9b

    Earnings

    Last Reported Earnings
    Mar 31, 2025
    Next Reporting Earnings
    Aug 05, 2025
    Earnings per share (EPS)
    118.27
    Gross Margin
    52.32%
    Net Profit Margin
    15.19%
    Debt/Equity Ratio
    84.9%

    Shin Nippon Biomedical Laboratories, Ltd. Competitors

     
     
     
     
     
     
     
     
     
     
     
     

    About 2395

    Founded
    1957
    Employees
    1436
    CEO
    Ryoichi Nagata
    WebsiteView website
    www.snbl.co.jp

    Shin Nippon Biomedical Laboratories, Ltd., a contract research organization, engages in the transactional research and medipolis businesses in Japan and internationally. It offers non-clinical studies, including single/repeated dose toxicity studies, antigenicity studies, skin sensitization studies, genotoxicity studies, carcinogenicity studies, local irritation studies, inhalation toxicity studies, TK studies, characteristic studies, stability studies, dependence studies, reproductive and developmental toxicity studies, safety pharmacological studies, and pharmacokinetic studies. The company also engages in the investigator brochure preparation support, clinical trial protocol creation support, clinical trial medical institution, investigational drug allocation, clinical trial request/contract, monitoring, quality management, data management, statistical analysis work, comprehensive report creation support, electronic application support, regulatory affairs consulting, and creating informed consent documents support services. In addition, it provides site management organization services for clinical trials; clinical contract research organization services; and translational research services, including research and development of vaccines and therapeutic drugs, antibody drugs, nucleic acid drugs, peptide drugs, gene therapy, and regenerative medicines. Further, the company is involved in the operates geothermal power generation; operates hotel accommodation facilities; and wellbeing businesses, as well as provides cleaning, clerical work, and welfare services. Shin Nippon Biomedical Laboratories, Ltd. was founded in 1957 and is headquartered in Kagoshima, Japan.

    Japanese Market Performance

    • 7 Days: -0.2%
    • 3 Months: 8.5%
    • 1 Year: 4.8%
    • Year to Date: 6.2%
    Over the last 7 days, the market has remained flat, with no particular sector making any big moves this week. Meanwhile, the market is actually up 4.8% over the past year. As for the next few years, earnings are expected to grow by 7.7% per annum. Market details ›
    Companies across the globe are beginning to pay attention to agentic AI. It’s also a term you’re likely to hear a lot during earnings season. In fact, it came up 26 times during...
    Continue reading